Patents by Inventor Grethe Norskov Rasmussen
Grethe Norskov Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240066142Abstract: The present invention describes a uPAR (urokinase Plasminogen Activator Receptor)-targeting conjugate comprising: —a fluorophore; —a molecule binding to the receptor; and—a linker group which covalently links the fluorophore to the molecule binding to the receptor, said linker group either being part of the molecule binding to the receptor or being a separate component of the uPAR (urokinase Plasminogen Activator Receptor)-targeting conjugate; wherein the uPAR (urokinase Plasminogen Activator Receptor)-targeting conjugate has a pharmacokinetic profile where a human TBR (tumor-to-background ratio) of at least 1.1 is reached within 3.5 hours post administration and where a human TBR of at least 1.5 is maintained at least 30 minutes before decreasing below 1.5, and wherein the uPAR-targeting conjugate is a human uPAR-targeting conjugate.Type: ApplicationFiled: January 14, 2022Publication date: February 29, 2024Inventors: Line HARTVIG, Grethe NORSKOV RASMUSSEN, Morten ALBRECHTSEN
-
Publication number: 20230117827Abstract: The present invention describes a composition comprising a fluorophore labelled uPAR-targeting component, a buffer and a surfactant, wherein the fluorophore labelled uPAR-targeting component is solubilized in the composition by means of the surfactant being present, and wherein the composition comprises a maximum of 10 wt % water, preferably a maximum of 5 wt % water.Type: ApplicationFiled: January 15, 2021Publication date: April 20, 2023Applicant: FLUOGUIDE A/SInventors: Grethe Nørskov Rasmussen, Andreas Kjær, Morten Albrechtsen, Line Hartvig
-
Publication number: 20210220442Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: March 29, 2021Publication date: July 22, 2021Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Publication number: 20210138090Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.Type: ApplicationFiled: January 15, 2021Publication date: May 13, 2021Applicant: FLUOGUIDE A/SInventors: Andreas KJAER, Morten PERSSON, Karina JUHL, Sorel KURBEGOVIC, Michael PLOUG, Knud Jørgen JENSEN, Kasper Kildegaard SØRENSEN, Anders CHRISTENSEN, Line HARTVIG, Grethe Nørskov RASMUSSEN, Morten ALBRECHTSEN
-
Patent number: 10960053Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: GrantFiled: September 28, 2018Date of Patent: March 30, 2021Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Publication number: 20200390864Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulation comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.Type: ApplicationFiled: August 28, 2020Publication date: December 17, 2020Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
-
Patent number: 10799563Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.Type: GrantFiled: November 17, 2015Date of Patent: October 13, 2020Assignee: Ascendis Pharma Endocrinology DivisionInventors: Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
-
Publication number: 20200261544Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: ApplicationFiled: May 5, 2020Publication date: August 20, 2020Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Patent number: 10682395Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: GrantFiled: February 21, 2018Date of Patent: June 16, 2020Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Publication number: 20190192634Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: September 28, 2018Publication date: June 27, 2019Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Patent number: 10098930Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: GrantFiled: January 19, 2016Date of Patent: October 16, 2018Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
-
Publication number: 20180185452Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: ApplicationFiled: February 21, 2018Publication date: July 5, 2018Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Patent number: 9919033Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: GrantFiled: November 1, 2016Date of Patent: March 20, 2018Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Publication number: 20170354716Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.Type: ApplicationFiled: November 17, 2015Publication date: December 14, 2017Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
-
Publication number: 20170056477Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: ApplicationFiled: November 1, 2016Publication date: March 2, 2017Applicant: Ascendis Pharma Growth Disorders Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Patent number: 9511122Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: GrantFiled: December 15, 2010Date of Patent: December 6, 2016Assignee: Ascendis Pharma Growth Disorders Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Publication number: 20160206702Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: January 19, 2016Publication date: July 21, 2016Applicant: Ascendis Pharma Growth Disorders Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
-
Patent number: 9272048Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: GrantFiled: April 29, 2009Date of Patent: March 1, 2016Assignee: Ascendis Pharma Growth Disorders Division A/SInventors: Harald Rau, Susanne Kinderman, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
-
Publication number: 20120322721Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: ApplicationFiled: December 15, 2010Publication date: December 20, 2012Inventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Publication number: 20110112021Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: April 29, 2009Publication date: May 12, 2011Applicant: Ascendis Pharma ASInventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe